Skip to main content

Advertisement

Log in

Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales’ disease

Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

To report the occurrence of secondary rhegmatogenous retinal detachment (RRD) after intravitreal bevacizumab injection in patients with Eales’ disease.

Methods

This is a retrospective, non-controlled, comparative case series. We reviewed 14 eyes of 14 patients with Eales’ disease who had received pretreatment with intravitreal bevacizumab (1.25 mg/0.05 ml) and subsequently undergone a pars plana vitrectomy for non-resolving vitreous hemorrhage and/or tractional retinal detachment. Clinical records were reviewed. The primary outcome measure was the occurrence of secondary RRD after intravitreal bevacizumab injection.

Results

Four patients had developed secondary RRD, with retinal breaks that were localized to the base of tractional retinal bands, within 1 week of receiving intravitreal bevacizumab. On comparative analysis, median age of patients who had developed secondary RRD was 26.5 years, significantly less than the median age of 33.5 years in the rest (P = 0.022). Median post-operative best-corrected visual acuity (BCVA) in patients who developed secondary RRD was logMAR 0.7 (0.3–0.8), significantly worse than the BCVA of logMAR 0.3 (0.0–0.5) in the rest (P = 0.015). None of the patients who developed secondary RRD had a complete posterior vitreous detachment (PVD) at presentation.

Conclusion

Intravitreal bevacizumab injections may be associated with the serious complication of secondary RRD in patients of Eales’ disease within 7 days of injection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Atmaca LS, Nagpal PN (1998) Eales’ disease: medical, laser, and surgical treatments. Ophthalmol Clin North Am 11(4):619–626

    Article  Google Scholar 

  2. Das T, Biswas J, Kumar A, Nagpal PN, Namperumalsamy P, Patnaik B, Tewari HK (1994) Eales’ disease. Indian J Ophthalmol 42(1):3–18

    PubMed  CAS  Google Scholar 

  3. Eales H (1882) Primary retinal haemorrhage in young men. Ophthalmic Rev 1:41–46

    Google Scholar 

  4. Patnaik B, Nagpal PN, Namperumalsamy P, Kalsi R (1998) Eales’ disease: clinical features, pathophysiology, etiopathogenesis. Ophthalmol Clin North Am 11(4):601–617

    Article  Google Scholar 

  5. Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, Ramakrishnan S (2002) Eales disease—an update. Surv Ophthalmol 47(3):197–214

    Article  PubMed  Google Scholar 

  6. Kumar A, Tiwari HK, Singh RP, Verma L, Prasad N (2000) Comparative evaluation of early vs deferred vitrectomy in Eales’ disease. Acta Ophthalmol Scand 78(1):77–78

    Article  PubMed  CAS  Google Scholar 

  7. Shanmugam MP, Badrinath SS, Gopal L, Sharma T (1998) Long term visual results of vitrectomy for Eales' disease complications. Int Ophthalmol 22(1):61–64

    Article  PubMed  CAS  Google Scholar 

  8. Shukla D, Kanungo S, Prasad NM, Kim R (2007) Surgical outcomes for vitrectomy in Eales’ disease. Eye 22(7):900–904

    Article  PubMed  Google Scholar 

  9. El-Asrar AM, Al-Kharashi SA (2002) Full panretinal photocoagulation and early vitrectomy improve prognosis of retinal vasculitis associated with tuberculoprotein hypersensitivity (Eales’ disease). Br J Ophthalmol 86(11):1248

    Article  PubMed  Google Scholar 

  10. Perentes Y, Chan CC, Bovey E, Uffer S, Herbort CP (2002) Massive vascular endothelium growth factor (VEGF) expression in Eales’ disease [Massive Expression von vascular Endothelium Growth Factor (VEGF) in einem Fall von Eales’ Krankheit]. Klin Monatsbl Augenheilkd 219:311–314

    Article  PubMed  Google Scholar 

  11. Kumar A, Sinha S (2007) Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab. Can J Ophthalmol 42(2):335–336

    Article  PubMed  Google Scholar 

  12. Küçükerdönmez C, Akova YA, Yilmaz G (2008) Intravitreal injection of bevacizumab in Eales' disease. Ocul Immunol Inflamm 16(1–2):63–65

    Article  PubMed  Google Scholar 

  13. Chanana B, Azad RV, Patwardhan S (2010) Role of intravitreal bevacizumab in the management of Eales’ disease. Int Ophthalmol 30(1):57–61

    Article  PubMed  Google Scholar 

  14. Raju B, Raju NSD, Raju AS, Rajamma SP (2009) Spontaneous relief of vitreomacular traction and regression of neovascularization in Eales’ disease after intravitreal injection of bevacizumab. Retinal Cases Brief Rep 3(2):128–129

    Article  Google Scholar 

  15. Patwardhan SD, Azad R, Shah BM, Sharma Y (2011) Role of intravitreal bevacizumab in Eales’ disease with dense vitreous hemorrhage: a prospective randomized control study. Retina 31(5):866–870

    Article  PubMed  CAS  Google Scholar 

  16. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26(3):275

    Article  PubMed  Google Scholar 

  17. Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr, Davis MD, Goldbaum M, Guyer DR, Barrett K (2006) Patel M (2006) Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113(1):23

    Article  PubMed  Google Scholar 

  18. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113(10):1695–1705

    Article  PubMed  Google Scholar 

  19. Chen E, Park CH (2006) Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 26(6):699

    Article  PubMed  Google Scholar 

  20. Arevalo JF, Maia M, Flynn HW, Saravia M, Avery RL, Wu L, Farah ME, Pieramici DJ, Berrocal MH, Sanchez JG (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92(2):213

    Article  PubMed  CAS  Google Scholar 

  21. Abdelhakim MASE, Macky TA, Mansour KAG, Mortada HA (2011) Bevacizumab (Avastin) as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Ophthalmic Res 45(1):23–30

    Article  PubMed  CAS  Google Scholar 

  22. Cheema RA, Mushtaq J, Al-Khars W, Al-Askar E, Cheema MA (2010) Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage. Retina 30(10):1646

    Article  PubMed  Google Scholar 

  23. Sigelman J, Ozanics V (1982) Retina. In: Jakobiec FA (ed) Ocular anatomy, embryology and teratology. Harper and Rowe, Philadelphia, pp 456–459

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Atul Kumar.

Additional information

The authors have no proprietary interest in the present study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, A., Sehra, S.V., Thirumalesh, M.B. et al. Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales’ disease. Graefes Arch Clin Exp Ophthalmol 250, 685–690 (2012). https://doi.org/10.1007/s00417-011-1890-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-011-1890-7

Keywords

Navigation